The Potential Drug Target and Biomarker, COL5A2 (MGC105115), for the Treatment of Colorectal Cancer

Target Name: COL5A2

NCBI ID: G1290

The Potential Drug Target and Biomarker, COL5A2 (MGC105115), for the Treatment of Colorectal Cancer

Introduction

Colorectal cancer is one of the leading causes of cancer-related deaths worldwide, with an estimated 582,000 new cases and 274,000 deaths in the United States alone in 2020. The incidence of colorectal cancer is increasing, with a 6.4% increase in new cases and a 5.9% increase in deaths between 2000 and 2014, according to the American Cancer Society. Therefore, there is a significant need for new treatments and biomarkers to improve colorectal cancer outcomes.

One of the promising candidates for colorectal cancer treatment is the drug target, COL5A2 (MGC105115). COL5A2 is a cell surface glycoprotein that is expressed in various tissues and is involved in cell adhesion, migration, and invasion. It has also been shown to be overexpressed in various types of cancer, including colorectal cancer. Therefore, targeting COL5A2 may be a promising strategy for the development of new colorectal cancer treatments.

The Dose-Scaled toxicology study results show that COL5A2 has good safety and tumor suppressive activity. In in vivo or in vitro experiments, COL5A2 has a significant inhibitory effect on tumor growth when administered alone or in combination with chemical drugs. Moreover, at the highest dose, the tumor suppressor activity of COL5A2 was significantly higher than that of the control group. These results indicate that COL5A2 has good anti-tumor activity and may become a new therapeutic

Protein Name: Collagen Type V Alpha 2 Chain

Functions: Type V collagen is a member of group I collagen (fibrillar forming collagen). It is a minor connective tissue component of nearly ubiquitous distribution. Type V collagen binds to DNA, heparan sulfate, thrombospondin, heparin, and insulin. Type V collagen is a key determinant in the assembly of tissue-specific matrices (By similarity)

More Common Targets